Literature DB >> 31897926

Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.

Ryota Tamura1, Yukina Morimoto1, Mizuto Sato1, Yuki Kuranari1, Yumiko Oishi1, Kenzo Kosugi1, Kazunari Yoshida1, Masahiro Toda2.   

Abstract

BACKGROUND: Neurofibromatosis type 2 (NF2) patients uniformly develop multiple schwannomas. The tumor-microenvironment (TME) is associated with hypoxia and consists of immunosuppressive cells, including regulatory T cells (Tregs) and tumor-associated macrophages (TAMs). The hypoxic TME of NF2 schwannomas remains unclear. In addition, no comparative study has investigated immunosuppressive cells in NF2 and sporadic schwannomas.
METHODS: In 22 NF2 and 21 sporadic schwannomas, we analyzed the immunohistochemistry for Ki-67, hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2, platelet derived growth factor receptor-beta (PDGFR-β), programmed cell death-1 (PD-1)/ programmed cell death ligand-1 (PD-L1), Foxp3, CD163, CD3, and CD8 to assess the immunosuppressive TME.
RESULTS: Most vessels in sporadic schwannomas exhibited slight or negative VEGFR1 and 2 expressions with pericytes coverage. In contrast, large vessels in NF2 schwannomas exhibited strong VEGFR1 and 2 expressions without pericytes. The number of CD3+, CD8+, and CD163+ cells was significantly higher in NF2 schwannomas than in sporadic ones. The expression of PD-L1 and nestin positive cell ratio was higher in NF2 schwannomas than that in sporadic ones. The number of CD163+ cells, nestin positive cell ratio, and HIF-1α expression were significantly associated with shorter progression-free survival in NF2 schwannomas.
CONCLUSIONS: This study presents the clinicopathological features of the differences in immunosuppressive cells and the expression of immune checkpoint molecules between NF2 and sporadic schwannomas. Hypoxic TME was first detected in NF2-schwannomas, which was associated with the tumor progression.

Entities:  

Keywords:  Hypoxia; NF2; PD-1; PD-L1; Schwannoma; Treg: TAM

Mesh:

Substances:

Year:  2020        PMID: 31897926     DOI: 10.1007/s11060-019-03388-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  51 in total

1.  Microanatomical localization of PD-1 in human tonsils.

Authors:  Yoshiko Iwai; Taku Okazaki; Hiroyuki Nishimura; Akemi Kawasaki; Hideo Yagita; Tasuku Honjo
Journal:  Immunol Lett       Date:  2002-10-01       Impact factor: 3.685

Review 2.  Management of the patient and family with neurofibromatosis 2: a consensus conference statement.

Authors:  D G R Evans; M E Baser; B O'Reilly; J Rowe; M Gleeson; S Saeed; A King; S M Huson; R Kerr; N Thomas; R Irving; R MacFarlane; R Ferner; R McLeod; D Moffat; R Ramsden
Journal:  Br J Neurosurg       Date:  2005-02       Impact factor: 1.596

Review 3.  Trophic macrophages in development and disease.

Authors:  Jeffrey W Pollard
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

4.  VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.

Authors:  Magali Terme; Simon Pernot; Elie Marcheteau; Federico Sandoval; Nadine Benhamouda; Orianne Colussi; Olivier Dubreuil; Antoine F Carpentier; Eric Tartour; Julien Taieb
Journal:  Cancer Res       Date:  2012-10-29       Impact factor: 12.701

5.  Molecular mechanisms of tumor angiogenesis.

Authors:  Safiyyah Ziyad; M Luisa Iruela-Arispe
Journal:  Genes Cancer       Date:  2011-12

Review 6.  The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.

Authors:  Ryota Tamura; Toshihide Tanaka; Yasuharu Akasaki; Yuichi Murayama; Kazunari Yoshida; Hikaru Sasaki
Journal:  Med Oncol       Date:  2019-11-11       Impact factor: 3.064

7.  Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration.

Authors:  Aurore Picry; Nicolas-Xavier Bonne; Juliette Ding; Rabih Aboukais; Jean-Paul Lejeune; Marc Baroncini; Frédérique Dubrulle; Christophe Vincent
Journal:  Laryngoscope       Date:  2016-04-14       Impact factor: 3.325

8.  PD-1 inhibits antiviral immunity at the effector phase in the liver.

Authors:  Yoshiko Iwai; Seigo Terawaki; Masaya Ikegawa; Taku Okazaki; Tasuku Honjo
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

9.  The treatment of a large acoustic tumor with fractionated stereotactic radiotherapy.

Authors:  Shearwood McClelland; Bruce J Gerbi; Kwan H Cho; Walter A Hall
Journal:  J Robot Surg       Date:  2007-08-28

10.  PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors:  Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962

View more
  4 in total

Review 1.  Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment.

Authors:  Cathal J Hannan; Daniel Lewis; Claire O'Leary; Carmine A Donofrio; Dafydd G Evans; Emma Stapleton; Simon R Freeman; Simon K Lloyd; Scott A Rutherford; Charlotte Hammerbeck-Ward; David Brough; Stuart M Allan; David Coope; Andrew T King; Omar N Pathmanaban
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-10

2.  Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth.

Authors:  Sherif G Ahmed; Giulia Oliva; Manlin Shao; Xinhui Wang; John J Mekalanos; Gary J Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-08       Impact factor: 12.779

Review 3.  A Critical Overview of Targeted Therapies for Vestibular Schwannoma.

Authors:  Ryota Tamura; Masahiro Toda
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 4.  Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.

Authors:  Ryota Tamura
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.